Reynolds v. Behrman Brothers Management Corporation

CourtDistrict Court, S.D. New York
DecidedApril 23, 2020
Docket1:19-cv-05842
StatusUnknown

This text of Reynolds v. Behrman Brothers Management Corporation (Reynolds v. Behrman Brothers Management Corporation) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Reynolds v. Behrman Brothers Management Corporation, (S.D.N.Y. 2020).

Opinion

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK -- ---------------------------------------------------------- X : THOMAS E. REYNOLDS, AS TRUSTEE, : Plaintiff, : 19 Civ. 5842 (LGS) : -against- : OPINION AND ORDER : BEHRMAN BROTHERS MANAGEMENT : CORPORATION, : Defendant. : ------------------------------------------------------------ X

LORNA G. SCHOFIELD, District Judge: Plaintiff, Thomas E. Reynolds, the Chapter 7 Trustee of Atherotech Holdings, Inc. (“Holdings”) and Atherotech, Inc. (“Atherotech”) (together, “Debtors”), bring this breach of contract action against Debtors’ former financial advisor, Defendant Behrman Brothers Management Corporation (“BBMC”). Defendant moves to dismiss the Amended Complaint (the “Complaint”)1 on grounds that: (1) the Complaint fails to identify any contract provision Defendant breached, (2) the alleged misconduct is subject to an exculpation clause, (3) the Complaint fails to plead damages, and (4) the claims are time barred. For the reasons below, Defendant’s motion to dismiss is granted. Plaintiff may seek leave to amend consistent with this Opinion.

1 The operative Amended Complaint was filed on December 17, 2019, after the motion to dismiss was fully briefed. Because the Amended Complaint does not make any changes material to the motion, the parties agreed -- and the Court so-ordered -- that the motion be construed to apply to the Amended Complaint. See Order at Dkt. No. 38. BACKGROUND The following facts are taken from the Complaint, documents integral to or incorporated in the Complaint by reference, and materials of which judicial notice may be taken, and these facts are accepted as true for purposes of this motion only.2 See Goel v. Bunge, Ltd., 820 F.3d

554, 559 (2d Cir. 2016); accord St. Clair-Hibbard v. Am. Fin. Tr., Inc., No. 18 Civ. 1148, 2019 WL 4601720, at *3 (S.D.N.Y. Sept. 23, 2019). A. The Financial Advisor Agreement Atherotech was a medical diagnostics company that, among other things, developed a blood cholesterol test called the “VAP Test.” Holdings was Atherotech’s parent company. On December 23, 2010, Behrman Capital Fund IV, LP (“Fund IV”), a private equity fund of non- party Behrman Capital, acquired a 94% ownership stake in Holdings, and in turn, Atherotech. That same date, Holdings and Defendant BBMC, another Behrman Capital entity, entered into the “Financial Advisor Agreement” (the “Agreement”) -- the subject of this dispute. The Agreement is expressly governed by New York law.

Under Section 1 of the Agreement, Defendant agreed “to provide [advisory] services” to Debtors on various issues, including: “management advisory services . . . in connection with . . . growth strategies, operational strategies, business partnership strategies” (§ 1(a)(i)(A)); “reviewing and approving annual financial budgets” (§ 1(a)(i)(F)); “[a]dvising [Debtors] on all aspects of their capital structure, including appropriate levels of debt and equity, which may include . . . sourcing, arranging and structuring debt and equity financing for [Debtors and] . . . advising [Debtors] with respect to appropriate cash management practices (§§ 1(a)(ii)(B)-(D)).

2 In support of the motion, Defendants filed full copies of the Agreement at issue and a copy of the United States Department of Health and Human Services’ Special Fraud Alert. Both of these are integral to and incorporated into the Complaint. The Agreement provides further that Defendant “will devote such time and effort in providing the services contemplated hereby as it deems reasonably necessary or appropriate; provided, that . . . [Defendant] reserves the right at any time not to provide services hereunder” (§ 1(b) (emphasis in original)).

Under Section 13 of the Agreement, in a provision entitled “Indemnification; Contribution,” Holdings: agrees to indemnify and hold harmless [Defendant] and its affiliates [each of which is an “Indemnified Party”] . . . from and against . . . any action, claim, proceeding or investigation . . . whether or not such Indemnified Party is a party and whether or not such action, claim, litigation, proceeding or investigation is initiated or brought by the Company [Holdings]. . . . . The Company also agrees that no Indemnified Party shall have any liability (whether direct or indirect, in contract or tort or otherwise) to the Company related to or arising out of [BBMC’s] retention pursuant to or performance of the services contemplated by this Agreement, except to the extent that the Advisor’s conduct in connection with such retention or performance is found in a final, non- appealable judgment by a court of competent jurisdiction to have constituted willful misconduct or gross negligence.

(§ 13(a)).

B. Alleged Breaches The Complaint alleges that Defendant breached the Agreement in three ways, by: (1) advising Atherotech to employ a growth strategy that depended on the payment of illegal process and handling fees (“P&H Fees”) to physician customers, (2) orchestrating a June 28, 2013, Dividend Recapitalization (“Dividend Recap”), to benefit Defendant-affiliated shareholders of Atherotech, before Atherotech faced liability for P&H Fees, and (3) failing to devise a contingency plan for Atherotech’s business after it was forced to stop paying P&H Fees in July 2014. Defendant’s actions contributed to the company’s eventual financial collapse. Debtors filed voluntary Chapter 7 bankruptcy petitions in March 2016. With respect to growth strategy, Atherotech’s business model included paying P&H Fees to physician customers. The fees covered the costs of physicians’ packaging and mailing patient blood samples to Atherotech’s laboratory, where Atherotech then performed the VAP Tests. Around 2005, Atherotech stopped paying P&H Fees, because it “conceded [their] illegality” in

light of United States Department of Health and Human Services (“HHS”) guidance. But around 2009, Atherotech resumed paying the fees, because its competitors were doing so. In 2011, Defendant advised Atherotech to grow its business by increasing direct sales to physicians. Defendant knew the strategy relied on P&H Fees and would “increas[e] the contingent liabilities of Atherotech.” The Department of Justice (“DOJ”) in 2012 began investigating whether Atherotech’s P&H Fees violated anti-kickback laws and the False Claims Act. As of June 2013, Debtors had approximately $35,691,000 in contingent liability associated with the possible repayment of Medicare reimbursements under the False Claims Act, subject to trebling for a total of approximately $107 million. On June 25, 2014, HHS issued a “Special Fraud Alert, Laboratory Payments to Referring Physicians” (the “Fraud Alert”). The Fraud Alert stated that

commercial payments to physicians, for handling and mailing blood samples, are prohibited “if even one purpose of the payment is to induce or reward referrals of Federal health care program business.” Because Medicare reimburses physicians for blood sample handling, the additional fees are more likely to have an “illegitimate purpose.” From 2011 to 2014, while Defendant was advising Atherotech, a substantial portion of the company’s blood samples qualified for Medicare reimbursement.3 In July 2014, Atherotech stopped paying P&H Fees.

3 According to the Complaint, Atherotech itself filed Medicare claims and received reimbursement related to the blood samples, rather than the physicians who handled and mailed in blood samples. The Special Fraud Alert describes only the practice of physicians seeking Medicare reimbursement and also being paid by a clinical laboratory for services. The The Complaint also alleges that the Dividend Recap, which closed during the DOJ investigation on June 28, 2013, breached the Agreement.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Cruz v. FXDirectDealer, LLC
720 F.3d 115 (Second Circuit, 2013)
Starr v. Sony BMG Music Entertainment
592 F.3d 314 (Second Circuit, 2010)
Greenfield v. Philles Records, Inc.
780 N.E.2d 166 (New York Court of Appeals, 2002)
C3 Media & Marketing Group, LLC v. Firstgate Internet, Inc.
419 F. Supp. 2d 419 (S.D. New York, 2005)
Schonfeld v. Hilliard
62 F. Supp. 2d 1062 (S.D. New York, 1999)
Freund v. Washington Square Press, Inc.
314 N.E.2d 419 (New York Court of Appeals, 1974)
Orlander v. Staples, Inc.
802 F.3d 289 (Second Circuit, 2015)
United States Ex Rel. Ladas v. Exelis, Inc.
824 F.3d 16 (Second Circuit, 2016)
Callanan v. . K., A.C. L.C.R.R. Co.
92 N.E. 747 (New York Court of Appeals, 1910)
Henry v. Bank of America
2017 NY Slip Op 1436 (Appellate Division of the Supreme Court of New York, 2017)
Kenford Co. v. County of Erie
537 N.E.2d 176 (New York Court of Appeals, 1989)
Awards.com v. Kinko's, Inc.
42 A.D.3d 178 (Appellate Division of the Supreme Court of New York, 2007)
Yenrab, Inc. v. 794 Linden Realty, LLC
68 A.D.3d 755 (Appellate Division of the Supreme Court of New York, 2009)
Atkins Nutritionals, Inc. v. Ernst & Young, LLP
301 A.D.2d 547 (Appellate Division of the Supreme Court of New York, 2003)
Mariah Re Ltd. v. American Family Mutual Insurance
52 F. Supp. 3d 601 (S.D. New York, 2014)

Cite This Page — Counsel Stack

Bluebook (online)
Reynolds v. Behrman Brothers Management Corporation, Counsel Stack Legal Research, https://law.counselstack.com/opinion/reynolds-v-behrman-brothers-management-corporation-nysd-2020.